Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Musculoskeletal Drugs in Phase II Clinical Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              Fulcrum Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod in FSHD

              Contact the Supplier

              Lead Product(s): Losmapimod

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 26, 2020

              Details:

              An open label extension for participants in ReDUX4 who have completed 24 weeks of dosing has also initiated, providing the opportunity for patients randomized to losmapimod to continue treatment.

              Dyve Biosciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout

              Contact the Supplier

              Lead Product(s): DYV-700

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2020

              Details:

              Dyve’s Phase 2 trial is designed to enroll 300 subjects across 20 trial centers in the U.S.

              Fulcrum Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded...

              Contact the Supplier

              Lead Product(s): Losmapimod

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 29, 2020

              Details:

              The Phase 1 clinical trial of losmapimod in patients with FSHD, indicated that losmapimod was generally well tolerated and achieved dose-dependent concentrations in plasma and muscle.

              Medivir

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Medivir's Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine

              Contact the Supplier

              Lead Product(s): MIV-711

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 20, 2020

              Details:

              The study demonstrated significant effect on changes in bone and cartilage degradation after six months of treatment with MIV-711.

              Ultragenyx Pharmaceutical

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumo...

              Contact the Supplier

              Lead Product(s): Burosumab

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 14, 2020

              Details:

              The sBLA package includes data from two single-arm Phase 2 studies including 14 adult patients conducted by Ultragenyx in the U.S. and 13 adult patients conducted by Kyowa Kirin in Japan.

              Catabasis Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              WRIB

              Participation Not Confirmed

              Update your events

              Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystr...

              Contact the Supplier

              Lead Product(s): Edasalonexent

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Duchenne UK

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership January 08, 2020

              Details:

              The partnership is to evaluate Edasalonexent a novel NF-kB inhibitor, in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial.

              PharmaCompass__DigitalAd